Bleeding Disorders

Events and Conferences: Bleeding Disorders Conference August 13–15

Thanks to Elaine Benoit, PBI’s marketing guru, for recent updates to our Events and Conferences Calendar. This week is the NBDF’s Bleeding Disorders Conference in Orlando, FL, USA, August 13–15. It’s not too late to register. Our colleagues at George King Bio-Medical will exhibit at booth 100. If you don’t see your hemostasis-related event or […]

Review: AI Designing the Future of Hemostasis

Check your medical library for this review article on AI-based peptide design to modify the GPIbα-VWF interaction in platelet-type von Willebrand disease: Kazmirchuk TDD, Wang J, Corbette J, et al. Designing the future of hemostasis. Semin Thromb Hemost. 2026 Jun 9. doi: 10.1055/a-2885-4368. PMID: 42225137. Abstract Bleeding disorders arising from dysfunctional platelet-protein interactions pose a […]

Bleeding Disorders

July 2026 QQ Summary: VWD Therapeutic

Our July 2026 QQ asked: What VWD therapeutic is NOT a replacement factor? Our 24 participants responded… Desmopressin: 18 (75%) Humate P: 1 (4%) Vonvendi: 4 (17%) Wilate: 1 (4%) VWD bleeding is first managed by applying “PRICE:” protection, rest, ice, compression, and elevation. Next, desmopressin (DDAVP) is administered via injection, infusion, and, in Europe, […]

Quick Question Archive

Emicizumab Therapy for the Newborn

Click for this Hemostasis Today column, Abdul Mannan: HAVEN 7 and the Future of Early Haemophilia Care. For a detailed follow-up to the HAVEN 7 trial, check your medical library for de Kovel M, Kenet G, Motwani J, et al; PedNet Study group. FVIII exposure, bleeding outcomes, and inhibitor development in 80 PUPs and MTPs […]

Bleeding Disorders

Why Does Blood Group O Reduce VWF?

Dr. Abdul Mannan’s LinkedIn post, “Why Does Blood Group O Reduce VWF?” presents the physiology of VWF in blood group O.

Bleeding Disorders

Why Clotting Patients Bleed

Abdul Mannan, Consultant Haematologist at Betsi Cadwaladr University Health Board, shared a column, Why Clotting Patients Bleed, in Hemostasis Today.

July 2026 QQ: VWD Therapeutic

We commemorate the 1926 publication by Finnish physician, Eric von Willebrand, Von Willebrand, E A (1926). “Hereditär pseudohemofili”. Finska Läkaresällskapets Handlingar (in Swedish). 68: 87–112. Dr. von Willebrand’s title, “Hereditary Pseudohemophilia,” was updated to our current name, von Willebrand disease, in the late 1930s, and the responsible protein was named von Willebrand factor in 1971. […]

Bleeding Disorders

June 2026 QQ Review: VWF Gain of Function

Our June 2026 QQ, which drew 30 responses, asked, “What VWD subtype is caused by a VWF gain of function?” Here are your responses: VWD type 1: 3 (10%) VWD subtype 2A: 1 (3%) VWD subtype 2B: 24 (80%) VWD subtype 2M: 2 (7%) VWD subtype 2N: 0 VWD type 1 is the quantitative form […]

Bleeding Disorders

A New Era in VWD Treatment

Click here for an informative LinkedIn/Hemostasis Today post from Shadi Tabibian, Deputy of Research at Blood Diseases Research Centers in Iran University of Medical Sciences, A New Era in VWD Treatment. For decades, the management of VWD has relied mainly on VWF concentrates, desmopressin, antifibrinolytic agents, and hormonal therapies. Although these treatments remain effective for […]

Bleeding Disorders

Review: Diagnosis and Management of Hemophilia A & B

Click here for an open-access review: Lim MY, Ardila J, Castaman G, et al. Diagnosis and management of hemophilia A and B. J Thromb Haemost. 2026;24:2341–54. doi: 10.1016/j.jtha.2026.04.005. PMID: 41967712. Abstract Hemophilia A and hemophilia B are inherited bleeding disorders caused by a deficiency or absence of coagulation factor FVIII and FIX, respectively. The severity […]

Bleeding Disorders

Load more

George Fritsma is a medical laboratory scientist, educator, and author. George is a member of the International Society on Thrombosis and Hemostasis, the International Society for Laboratory Hematology, and the American Society for Clinical Laboratory Science.

Cheat Sheets from George

Quick Question